Related Experiment Video

Updated: Jun 17, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Temsirolimus

Christian Stock1, Massimo Zaccagnini, Michael Schulze

  • 1Department of Urology, SLK-Kliniken Heilbronn GmbH, Medizinsche Klinik III, Germany. jens.rassweiler@slk-kliniken.de

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|January 15, 2010
PubMed

Insights

Temsirolimus offers significant survival benefits for advanced renal cell carcinoma (RCC) patients compared to interferon-alpha. This mTOR inhibitor demonstrated improved overall survival and response rates with fewer adverse events.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced renal cell carcinoma (RCC) presents a poor prognosis.
  • Current therapies like interferon-alpha (IFNalpha) have limitations.

Purpose of the Study:

  • To evaluate the efficacy and safety of temsirolimus in patients with advanced RCC.
  • To compare temsirolimus monotherapy against standard IFNalpha treatment.

Main Methods:

  • A large phase III clinical study was conducted.
  • Patients received a once-weekly intravenous (IV) infusion of temsirolimus (25 mg) or IFNalpha.
  • Overall survival, objective response rates, and adverse events were assessed.

Main Results:

  • Temsirolimus significantly improved median overall survival (10.9 vs. 7.3 months) compared to IFNalpha.
  • Objective response rates were higher with temsirolimus (8.6%) versus IFNalpha (4.8%).
  • Temsirolimus recipients experienced fewer grade 3 or 4 adverse events and fewer treatment withdrawals.

Conclusions:

  • Temsirolimus provides significant survival benefits for advanced RCC patients with poor prognosis.
  • Temsirolimus demonstrates a favorable safety profile compared to IFNalpha.
  • Temsirolimus represents an effective treatment option for advanced renal cell carcinoma.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...